Protective effect of apigenin on ovariectomy-induced bone loss in rats

Life Sciences

Volumn 82, Issue 25-26, 2008, Pages 1217-1223

  Park, Jeong A ^a   Ha, Sang Keun ^a   Kang, Tong Ho ^b   Oh, Myung Sook ^a   Cho, Min Hyoung ^a   Lee, Soo Yeol ^a   Park, Ji Ho ^a   Kim, Sun Yeou ^a  

^a Kyung Hee University   (South Korea)

^b Nambu University   (South Korea)

Author keywords

Apigenin; Osteoporosis; Ovariectomy; Uterus; Zoom in micro computed tomography

Indexed keywords

APIGENIN; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DIET; DRUG EFFECT; FEMALE; FEMUR NECK; FOOD INTAKE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; RAT; SPRAGUE DAWLEY RAT; TRABECULAR BONE;

ALKALINE PHOSPHATASE; ANIMALS; APIGENIN; BODY WEIGHT; BONE RESORPTION; DIET; ESTRADIOL; FEMALE; FEMUR NECK; ORGAN SIZE; OSTEOCALCIN; OVARIECTOMY; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED; UTERUS;

ANIMALIA; RATTUS;

EID: 44649178200     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.03.021     Document Type: Article

References (57)

1. Bahlous A., Kalai E., Hadj Salah M., Bouzid K., and Zerelli L. Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis. La Tunisie Médicale 84 (2006) 751-757
2. Bandyopadhyay S., Lion J.M., Mentaverri R., Ricupero D.A., Kamel S., Romero J.R., and Chattopadhyay N. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochemical Pharmacology 72 (2006) 184-197
3. Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic and Clinical Pharmacology and Toxicology 98 (2006) 288-296
4. Bilezikian J.P. Anabolic therapy for osteoporosis. International Journal of Fertility and Women's Medicine 50 2 (2005) 53-60
5. Brandi M.L. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcified Tissue International 61 (1997) S5-S8
6. Chun I.K., Cho M.H., Park J.H., and Lee S.Y. In vivo trabecular thickness measurement in cancellous bones: longitudinal rat imaging studies. Physiological Measurement 27 8 (2006) 695-702
7. Comalada M., Ballester I., Bailon E., Sierra S., Xaus J., Gálvez J., de Medina F.S., and Zarzuelo A. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochemical Pharmacology 72 8 (2006) 1010-1021
8. Compston J. Prevention of osteoporotic fractures in post-menopausal women. Best Practice and Research Clinical Endocrinology and Metabolism 14 2 (2000) 251-264
9. Compston J. How to manage osteoporosis after the menopause. Best Practice and Research Clinical Rheumatology 19 6 (2005) 1007-1019
10. Creasman W.T. Hormone replacement therapy after cancers. Current Opinion in Oncology 17 5 (2005) 493-499
11. Dang Z.C., and Lowik C. Dose-dependent effects of phytoestrogens on bone. Trends in Endocrinology and Metabolism 16 5 (2005) 207-213
12. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., and Jiang B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28 4 (2007) 858-864
13. Gallo D., Zannoni G.F., Apollonio P., Martinelli E., Ferlini C., Passetti G., Riva A., Morazzoni P., Bombardelli E., and Scambia G. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 12 5 (2005) 589-600
14. Garnero P., Sornay-Rendu E., Chapuy M.C., and Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. Journal of Bone and Mineral Research 11 3 (1996) 337-349
15. Garnero P., and Delmas P.D. Biochemical markers of bone turnover: clinical usefulness in osteoporosis. Annales de Biologie Clinique 57 2 (1999) 137-148
16. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., and Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 5223 (1995) 543-546
17. Hallworth R.B. Prevention and treatment of postmenopausal osteoporosis. Pharmacy World and Science 20 5 (1998) 198-205
18. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., and Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22 31 (2003) 4851-4859
19. Hiremath S.P., Badami S., Hunasagatta S.K., and Patil S.B. Antifertility and hormonal properties of flavones of Striga orobanchioides. European Journal of Pharmacology 391 1-2 (2000) 193-197
20. Hougee S., Sanders A., Faber J., Graus Y.M., van den Berg W.B., Garssen J., Smit H.F., and Hoijer M.A. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochemical Pharmacology 69 2 (2005) 241-248
21. Jordan V.C., Gapstur S., and Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute 93 19 (2001) 1449-1457
22. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone and Mineral 15 3 (1991) 175-191
23. Kanis J.A., McCloskey E.V., de Takats D., and Pande K. Clinical assessment of bone mass, quality and architecture. Osteoporosis International 9 (1999) S24-S28
24. Kazakia G.J., and Majumdar S. New imaging technologies in the diagnosis of osteoporosis. Reviews in Endocrine and Metabolic Disorders 7 1-2 (2006) 67-74
25. Ke H.Z., Chen H.K., Simmons H.A., Qi H., Crawford D.T., Pirie C.M., Chidsey-Frink K.L., Ma Y.F., Jee W.S., and Thompson D.D. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20 1 (1997) 31-39
26. Kelly P.J. Is osteoporosis a genetically determined disease?. British Journal of Obstetrics and Gynaecology 103 (1996) 26-27
27. Kimura M., Irahara M., Yasui T., Saito S., Tezuka M., Yamano S., Kamada M., and Aono T. The obesity in bilateral ovariectomized rats is related to a decrease in the expression of leptin receptors in the brain. Biochemical and Biophysical Research Communications 290 4 (2002) 1349-1353
28. Kurasawa K. Bone quality and biochemical markers. Clinical Calcium 15 6 (2005) 959-964
29. Li M., Shen Y., and Wronski T.J. Time course of femoral neck osteopenia in ovariectomized rats. Bone 20 1 (1997) 55-61
30. Meli R., Pacilio M., Raso G.M., Esposito E., Coppola A., Nasti A., Di Carlo C., Nappi C., and Di Carlo R. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology 145 7 (2004) 3115-3121
31. Mosekilde L. Assessing bone quality-animal models in preclinical osteoporosis research. Bone 17 (1995) 343S-352S
32. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., and Slootweg M.C. Growth hormone and bone. Endocrine Reviews 19 1 (1998) 55-79
33. Okahashi N., Nakamura I., Jimi E., Koide M., Suda T., and Nishihara T. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts. Journal of Bone and Mineral Research 12 7 (1997) 1116-1123
34. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis-the second decade. Endocrinology 139 6 (1998) 2659-2661
35. Patel D., Shukla S., and Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). International Journal of Oncology 30 1 (2007) 233-245
36. Picherit C., Coxam V., Bennetau-Pelissero C., Kati-Coulibaly S., Davicco M.J., Lebecque P., and Barlet J.P. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. The Journal of Nutrition 130 7 (2000) 1675-1681
37. Poole K.E., and Reeve J. Parathyroid hormone-a bone anabolic and catabolic agent. Current Opinion in Pharmacology 5 6 (2005) 612-617
38. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The Journal of Clinical Investigation 115 12 (2005) 3318-3325
39. Reinwald S., and Weaver C.M. Soy isoflavones and bone health: a double-edged sword?. Journal of Natural Products 69 3 (2006) 450-459
40. Ren P., Ji H., Shao Q., Chen X., Han J., and Sun Y. Protective effects of sodium daidzein sulfonate on trabecular bone in ovariectomized rats. Pharmacology 79 3 (2007) 129-136
41. Ribot C., and Tremollieres F. Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk. Presse Médicale 35 (2006) 1557-1563
42. Riggs B.L. Overview of osteoporosis. The Western Journal of Medicine 154 1 (1991) 63-77
43. Riggs B.L., Khosla S., and Melton III L.J. Sex steroids and the construction and conservation of adult skeleton. Endocrine Reviews 23 3 (2002) 279-302
44. Rodan G.A., and Martin T.J. Therapeutic approaches to bone disease. Science 289 5484 (2000) 1508-1514
45. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., and Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proceedings of the National Academy of Sciences of the United States of America 98 24 (2001) 13960-13965
46. Shukla S., and Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6 9 (2007) 1102-1114
47. Swissa-Sivan A., Statter M., Brooks G.A., Azevedo J., Viguie C., Azoury R., Greenfield C., Oman S., Leichter I., Zinker B.A., et al. Effect of swimming on prednisolone-induced osteoporosis in elderly rats. Journal of Bone and Mineral Research 7 2 (1992) 161-169
48. Takeuchi S. Morphological transformation of limb bones with growth. Kaibogaku Zasshi 75 2 (2000) 207-214
49. Teo J.C., Si-Hoe K.M., Keh J.E., and Teoh S.H. Relationship between CT intensity, micro-architecture and mechanical properties of porcine vertebral cancellous bone. Clinical Biomechanics 21 3 (2006) 235-244
50. Thompson D.D., Simmons H.A., Pirie C.M., and Ke H.Z. FDA guidelines and animal models for osteoporosis. Bone 17 (1995) 125S-133S
51. Usui T. Pharmaceutical prospects of phytoestrogens. Endocrine Journal 53 1 (2006) 7-20
52. Weitzmann M.N., and Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. The Journal of Clinical Investigation 116 5 (2006) 1186-1194
53. Withold W. Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. European Journal of Clinical Chemistry and Clinical Biochemistry 34 10 (1996) 785-799
54. Yin J., Tezuka Y., Subehan, Shi L., Nobukawa M., Nobukawa T., and Kadota S. In vivo anti-osteoporotic activity of isotaxiresinol, a lignan from wood of Taxus yunnanensis. Phytomedicine 13 1-2 (2006) 37-42
55. Yoneda N., Saito S., Kimura M., Yamada M., Iida M., Murakami T., Irahara M., Shima K., and Aono T. The influence of ovariectomy on ob gene expression in rats. Hormone and Metabolic Research 30 5 (1998) 263-265
56. Zanoli P., Avallone R., and Baraldi M. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia 71 (2000) S117-S123
57. Zhang J., Wang Y.J., and Xu J.L. Experimental study on prevention and treatment of osteoporosis by phytoestrogen. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi 24 3 (2004) 241-243